ACM
RLMD icon

Aquatic Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Aquatic Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-500
Closed -$9K – 1492
2022
Q2 		$9K Buy
500
+400
+400% +$8.72K ﹤0.01% 984
2022
Q1 		$3K Sell
100
-900
-90% -$18.6K ﹤0.01% 924
2021
Q4 		$23K Buy
+1,000
New +$22.2K 0.04% 558

Other funds holding RLMD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Aquatic Capital Management's RLMD Position: Q3 2022 in Review

Aquatic Capital Management sold out of Relmada Therapeutics (RLMD) in Q3 2022, closing a stake of 500 shares — an estimated $9K sold.

Aquatic Capital Management first reported a position in RLMD in Q4 2021 and held it in 3 quarters. The position peaked at $23K in Q4 2021. 134 funds tracked by Wall St. Rank hold RLMD as of Q3 2022.

  • Aquatic Capital Management reported no remaining Relmada Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Aquatic Capital Management sold 500 Relmada Therapeutics shares in Q3 2022, an estimated $9K.
  • Aquatic Capital Management first reported a position in Relmada Therapeutics in Q4 2021 and held it in 3 quarters.
  • Aquatic Capital Management's Relmada Therapeutics position peaked at $23K in Q4 2021.
  • 134 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2022.

Based on Aquatic Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.